Loading stock data…
NRX Pharmaceuticals, Inc. (NRXP)
$4.00+0.27 (+7.24%)
Market ClosedLast close Jun 29
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NRx Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.00 with a market capitalization of $166M. Wall Street consensus targets $42.00 (4 analysts), implying a +950.0% move over the next 12 months. The stock is currently 21% below its 52-week high of $5.05, remaining 48.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +950.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.07M↑ | $983,000↑ | $242,000 | $0 | $0 |
| Gross Profit | $437,000↓ | $575,000↑ | $145,000 | — | $0 |
| Operating Income | -$4.75M↓ | -$4.62M↓ | -$4.02M↓ | -$3.73M↑ | -$3.75M |
| Net Income | -$1.43M↓ | $360,000↑ | -$5.89M↑ | -$17.58M↓ | -$5.51M |
Peer Comparison
JNJUNHPFE
Fundamentals
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$165.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
177.63%
Volume
Today's trading volume
989,135
Recent News
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% a
NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
NRX Pharmaceuticals Inc (NRXP) reports significant progress in regulatory pathways and funding, despite increased operational losses and expenses.
NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), featuring a year-to-date gain of 52.77% and upside potential of 987.00%, secures a spot on our list of hot biotech stocks under $5 to buy. A clinical-stage biopharmaceutical company focused on bringing suicide-prevention drugs to market, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), just closed a capital raise that provides it with a fresh […]
Here is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street Analysts
With an upside potential of 1194.87%, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 13, Lucid Capital initiated coverage of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) with a Buy rating and a $49 price target. The firm stated that NRx is preparing to enter the approximately […]
NRx Pharmaceuticals Q1 Earnings Call Highlights
NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100. Founder,